Clinical trials: Cancer of the Fallopian Tube
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma
- Trial name
- NCT02446600
- Testing
- Biospecimen Collection, Carboplatin, Cediranib Maleate
- Where
- 356 sites in United States, Canada and 2 more
- Volunteers
- 579 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01447706
- Testing
- MM-121, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 223 people
- Sponsor
- Merrimack Pharmaceuticals
Cervical Cancer, Endometrial Cancer
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00287885
- Testing
- docetaxel
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Neoplasms
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer
To evaluate and to compare the effectiveness of CA-125 and HE4 serum levels in epithelial ovarian cancer (OC) in follow-up in terms of time to detection of elevation after the end of the first line treatment.
- Trial name
- NCT02687321
- Testing
- Determination of CA 125 and HE4, Computed tomography
- Where
- 20 sites in Czechia, Hungary and 4 more
- Volunteers
- 150 people
- Sponsor
- Brno University Hospital
Ovarian Cancer, Peritoneal Cancer
Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin
The goal of this clinical research study is to learn about the safety and tolerability of paclitaxel and carboplatin when given in combination with Avastin to patients with ovarian, primary peritoneal, or fallopian tube cancer.
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00652119
- Testing
- Paclitaxel, Carboplatin, Avastin
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Epithelial Ovarian Cancer, Peritoneal Cancer
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- MIRASOL (NCT04209855)
- Testing
- Mirvetuximab Soravtansine, Paclitaxel, Topotecan
- Where
- 214 sites in United States, Australia and 19 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Ovarian Cancer, Fallopian Tube Cancer
Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- PRESELECT-0 (NCT07022535)
- Testing
- KELIM, Carboplatin plus Paclitaxel, Interval debulking surgery
- Where
- Hong Kong
- Volunteers
- 18 people
- Sponsor
- The University of Hong Kong
Ovarian Cancer, Fallopian Tube Cancer
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
This study is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in PFS (compared to control subjects) and evaluate the safety and tolerability of AMG 386 in combination with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00479817
- Testing
- AMG 386, Paclitaxel
- Volunteers
- 161 people
- Sponsor
- Amgen
Fallopian Tube Carcinoma, Ovarian Carcinoma
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This research trial studies biomarkers in patients with previously untreated invasive ovarian epithelial, fallopian tube, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT01295489
- Testing
- Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gynecologic Oncology Group
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies the combination of pembrolizumab, bevacizumab, and low dose oral cyclophosphamide in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT02853318
- Testing
- Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Roswell Park Cancer Institute
Fallopian Tube Cancer, Ovarian Cancer
A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
purpose Primary endpoint To evaluate the 24 month disease free survival Second endpoints To evaluate the 24 month overall survival To analyze the toxicity and the quality of life
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01570582
- Testing
- carboplatin and paclitaxel
- Where
- South Korea
- Volunteers
- 314 people
- Sponsor
- Korean Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
This is a phase II study in patients with recurrent platinum resistant or refractory C5 high-grade serous, endometrioid or undifferentiated ovarian, primary peritoneal or fallopian tube cancer.
- Trial name
- NCT03188159
- Testing
- Vinorelbine
- Where
- 2 sites in Australia, Singapore
- Volunteers
- 36 people
- Sponsor
- National University Hospital, Singapore
Ovarian Carcinoma, Fallopian Tube Carcinoma
NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma
For patients with ovarian cancer and biologically related diseases, the implementation of genetic testing in the decision-making process could have an impact both on the risk management for the patient and his/her family, but…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- PERSONA-Ovary (NCT06972693)
- Testing
- BRCA testing
- Where
- Italy
- Volunteers
- 323 people
- Sponsor
- European Institute of Oncology
Malignant Neoplasm of Ovary, Malignant Neoplasm of Fallopian Tube
Debulking Surgery in Ovarian Cancer
The purpose of this study is to see if patients undergoing a laparoscopic surgery for removal of ovarian, fallopian tube, or primary peritoneal cancer following neoadjuvant chemotherapy (neoadjuvant- chemotherapy given before…
- Conditions
- Malignant Neoplasm of Ovary, Malignant Neoplasm of Fallopian Tube, Malignant Neoplasm of Peritoneum
- Trial name
- MIID-SOC (NCT03378128)
- Testing
- Diagnostic laparoscopy
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Case Comprehensive Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether receiving paclitaxel and carboplatin with epirubicin is more effective than…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004934
- Testing
- carboplatin, epirubicin hydrochloride, paclitaxel
- Where
- 18 sites in United States, Belgium and 8 more
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial investigates how well pembrolizumab and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent).
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT04387227
- Testing
- Carboplatin, Pembrolizumab, Computed Tomography
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Fallopian Tube Cancer, Ovarian Cancer
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
It is still not clear whether a positive AGO-score just selects patients with less aggressive biologic tumor behavior who as well would have had a positive outcome by chemotherapy only, or , if it is a score selecting patients…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- DESKTOPIII (NCT01166737)
- Testing
- Tumor Debulking Surgery (surgery in recurrent ovarian disease)
- Where
- 86 sites in Austria, Belgium and 10 more
- Volunteers
- 408 people
- Sponsor
- AGO Study Group
Fallopian Tube Carcinoma, Infectious Disorder
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
This phase I trial is studying the side effects of giving carboplatin and paclitaxel together with pegfilgrastim in treating patients with stage III or stage IV ovarian epithelial, fallopian tube, primary peritoneal, or…
- Conditions
- Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Ovarian Carcinosarcoma
- Trial name
- NCT00352300
- Testing
- Adjuvant Therapy, Carboplatin, Paclitaxel
- Where
- 11 sites in United States
- Volunteers
- 43 people
- Sponsor
- Gynecologic Oncology Group